Johnson & Johnson (JNJ) Declares $0.84 Quarterly Dividend; 2.4% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Johnson & Johnson (JNJ) PT Raised to $145 at Morgan Stanley
October 18, 2017 7:49 AM EDTMorgan Stanley raised its price target on Johnson & Johnson (NYSE: JNJ) to $145.00 (from $140.00) while maintaining a Overweight rating.
... MoreJohnson & Johnson (JNJ) PT Raised to $161 at Jefferies
October 18, 2017 7:30 AM EDTJefferies raised its price target on Johnson & Johnson (NYSE: JNJ) to $161.00 (from $160.00) while maintaining a Buy rating following beat and raise results.
Analyst Jeffrey Holford notes their revenue and adjusted EPS estimates remain well above consensus.
"The Pharma division remains under-modeled by... More
Johnson & Johnson (JNJ) PT Raised to $165 at Leerink Partners
October 18, 2017 7:03 AM EDTLeerink Partners raised its price target on Johnson & Johnson (NYSE: JNJ) to $165.00 (from $150.00) while maintaining a Outperform rating.
Analyst Danielle Antalffy said outperformance highlights momentum. 217/2018 outlook moves higher.
... MoreJohnson & Johnson (JNJ) PT Raised to $142 at Stifel on 3Q Earnings Report; 'Pharma Carries the Day, Hurricane Headwinds Encouragingly Modest
October 17, 2017 5:16 PM EDTStifel raised its price target on Johnson & Johnson (NYSE: JNJ) to $142.00 (from $140.00) while maintaining a Hold rating, following the company's third quarter earnings report.
Analyst Rick Wise notes a positive outlook, as the company reported third quarter earnings per share and revenue results above... More
Johnson & Johnson (JNJ) Wins Reversal of First St. Louis Talc-Cancer Verdict - Bloomberg
October 17, 2017 12:00 PM EDTJohnson & Johnson (NYSE: JNJ) Wins Reversal of First St. Louis Talc-Cancer Verdict - Bloomberg
... MoreDow pierces 23,000 but ends below milestone
October 17, 2017 7:41 AM EDTBy Caroline Valetkevitch
NEW YORK (Reuters) - The Dow Jones Industrial Average briefly broke above the 23,000-point mark for the first time on Tuesday, driven by strong earnings from UnitedHealth and Johnson & Johnson, but finished the session just below that milestone.
The blue-chip index, which surpassed similar 1,000-point marks three times previously this year, has been steadily inching higher and is up 2.6 percent so far this month, putting it on track for a seventh straight monthly advance.
The Dow may in the near term have a difficult time sustaining a move above 23,000, said Robert Pavlik, chief... More
Johnson & Johnson (JNJ) Tops Q3 EPS by 10c; Raises Outlook
October 17, 2017 6:42 AM EDTJohnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.90, $0.10 better than the analyst estimate of $1.80. Revenue for the quarter came in at $19.7 billion versus the consensus estimate of $19.28 billion.
GUIDANCE:
Johnson & Johnson raised its FY outlook. The company sees FY2017 EPS of... More
